The Science of Launching and Achieving Growth in Oncology

Patient Inspired. Outcomes Driven.
LAUNCHINGAND
ACHIEVING
GROWTHIN
ONCOLOGY

Copyright © 2019 Accenture All rights reserved.
New Science
Is a new mechanism, modality, indication or health
technology identified by the FDA or other regulatory
entity as having met an unmet need, exceeding
standard of care; often involves a technology
companion but can be the technology alone
2

3
NEWSCIENCEISCHANGINGTHEHEALTHCARE
LANDSCAPE
• 54% of industry sales by 2022 driven by new science
• 6-7 x’s higher investment in digital,
data and genomics by the industry leaders
• Emerging decision makers beyond doctors/HCPs,
such as patients, care givers, payers, pharmacies/
dispensers, and advocacy groups
• Growing importance of patient experience and
outcomes
• Shifting from price to value
…FUNDAMENTALLY CHANGING THE WAY WE SUCCESSFULLY
LAUNCH ONCOLOGY PRODUCTS IN THE FUTURE
GROWTH OF NEW SCIENCE… …IN THE EVOLVING ECOSYSTEM

4
NEWSCIENCEISDRIVINGEXCEPTIONALGROWTH
acrossmultipletherapeuticareas,butprimarilyinoncology
NEW SCIENCE % OF SALES IN THERAPEUTIC AREAS
Source: Accenture analysis, data provided by Evaluate Pharma

In this increasingly complex health
ecosystem, how are leading
oncology companies driving growth
and changing how they launch their
treatments?
5

RISE OF NEW
SCIENCE
INCREASE IN TREATMENT
CHOICES
CHANGING
ECONOMICS
6
3TRENDSINFLUENCINGGROWTHIN
ONCOLOGYINTHISNEWENVIRONMENT

COMPETITIONISACCELERATING
300+New oncology treatment
options by 20231,2
Breast
Lung
Leukemia
Prostate
Uterine
corpus
Colon& rectum
Melanoma
Liver
Non-Hodgkin
lymphoma
Kidney and
renal pelvis
Pancreas
Urinary
bladder
Thyroid
Oral cavity
& pharynx
0
30
60
90
120
150
180
210
240
270
300
0 20 40 60 80 100
PrevalenceofNewCasesby2022
(Thousands)
New Therapies by 2023
1 clinicaltrials.gov
2 Each successful phase II and III trial that leads to an
approval is defined as a new therapy
3 Historical FDA approval data is used for estimation
4Drugs that have already been approved and expected to
receive approvals in other indications
20% Novel treatments (60)3
80% New indications (launched
before)4
25%+ Combination therapies
7

8
…MAKINGPATIENTEXPERIENCEINCREASINGLY
IMPORTANT
Copyright © 2018 Accenture. All rights reserved.
Q5a. How much input do you currently have over the decision as to which new healthcare products and treatment options to select for your condition, from the full range of product and
treatment options available in the market, that are different to what you use today? Q5b. How much input do you want to have over the decision as to which new healthcare products and
treatment options to select for your condition, from the full range of product and treatment options available in the market, that are different to what you use today? Total (9234)
Current input over new healthcare
treatment decisions
Desired input over new
healthcare treatment decisions
44% 63%

Pinpoint 22biomarkers
Driven by 14distinct
technologies
Address 15indications
DECISIONMAKINGISINCREASINGLYCOMPLEX
Sources: 1 Transparency Market research, 2 https://www.fda.gov/,
36FDA approved
companion diagnostics2
Manufactured by 16
different companies as
of 2018
USE CASE FOR NON-SMALL-CELL
LUNG CANCER (NSCLC)
Current: A patient is typically tested for multiple biomarkers
simultaneously (ALK, EGFR, ROS, PD-L1). A targeted therapy is the first
choice if patient is eligible. If not, PD-L1 status is considered for I-O
therapy.2
Future: Comprehensive genome profiling + combination therapy
options will make decision making even more complex.
9
BIOMARKERS ALLOW FOR THE SEGMENTATION OF TUMOR MARKETS AND LEADING TO A
FAST GROWING COMPANION DIAGNOSTICS MARKET.
BY 2025, ONCOLOGY WILL BE 87% OF A $13.6B COMPANION DIAGNOSTICS MARKET1
ALK = anaplastic lymphoma kinase
EGFR = epidermal growth factor receptor
ROS = Proto-oncogene tyrosine-protein kinase
PD-L1 = Programmed death-ligand 1

10
…CLINICALPATHWAYSAREBEINGINCREASINGLY
IMPORTANTFORDECISIONMAKING
CLINICAL PATHWAYS ARE BEING INCREASINGLY USED TO AID DECISION MAKING
60%
of practice physicians
regularly use clinical
pathways in patient
care1
38%
of practices report using
practice generated
sources, as opposed to
• P4 (10%)
• payer generated (7.5%)
• hospital generated(7.5%)
• UPMC (6.25%),
• Innovent/US Oncology
(5%)2
54%
of practices routinely
measure physician
compliance with clinical
pathways3
42%
increase in the number of
oncology practices
reporting compliance
with a pathways program
from 2014 to 20164
Sources:1,2,3 Transparency ASCO National Oncology Practice Benchmark;4 http://pharmaceuticalcommerce.com

11
DECISIONMAKINGISINCREASINGLYCOMPLEX
PAYERS ARE USING HEALTH-BASED OUTCOMES TO DETERMINE REIMBURSEMENT
INNOVATION AGILITY IS A CONCERN
Only 21% of payers are capable of rolling
out a new episode of care program in less
than 6 months1
PAYERS LACK CAPABILITY TO
QUANTIFY VALUE
More than 50% of payers are not satisfied
with their current value-based analytics,
automation, and reporting capabilities2
HEALTH-BASED OUTCOMES
Conditional reimbursement rules and Performance Based
Risk Sharing Arrangements are emerging, where
performance is tracked in a defined patient population over
a pre-specified period of time, and amount or level of
reimbursement is based on outcomes achieved.
USE CASE
AstraZeneca and UK government agreed on deal where UK
pays for Lynparza for the first 15 months of treatment, then
AZ is responsible for the additional costs3
Sources:
1, 2 https://www.journalofclinicalpathways.com
3 https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/12045335/AstraZeneca-cancer-drug-approved-on-NHS-but-with-strings-attached.html

ACTIONSTOLAUNCH
NEWTREATMENTS
ANDACHIEVEGROWTH
INONCOLOGY
Copyright © 2019 Accenture All rights reserved. 12
▌ Simplify decision making for Oncologists and
patients.
▌ Consider the entire patient experience starting
with clinical trial design.
▌ Bring a steady stream of evidence that your
treatment delivers a better outcome in a real-
world setting.

SIMPLIFYDECISIONMAKING
FORONCOLOGISTSAND
PATIENTS
Ensure trial results are
easy to interpret in a
real-world setting.
Connect results to the
patient populations
and simplify
messaging so the
choice is clear to
oncologist and the
patient.
Move from informative
decision tools to aids
for actual decision
making in the clinic.
Raise awareness using
oncology conferences
(ASCO, ESMO, and
others).
Make it easy to work
with other physicians
(peers)
13

CONSIDERTHEENTIRE
PATIENTEXPERIENCE
STARTINGWITH
CLINICALTRIALDESIGN
▌Reduce dosing schedule requiring less
hospital visits by elongating the time
between doses (e.g. every four weeks vs.
every six weeks make a difference).
▌Different treatment administration
methods to completely eliminate travel to
infusion centers – Oral or sub-cutaneous.
14

BRINGASTEADYSTREAMOF
EVIDENCE
THATYOURTREATMENTDELIVERSABETTER
OUTCOMEINAREAL-WORLDSETTING
▌ Invest time and money to continuously create real-world
evidence (RWE) for clinical outcomes as payers increase
use of health-based outcomes to determine reimbursement.
▌ Be creative with your pricing method – use the full toolkit
(outcome based, indication-based pricing, etc.)
▌ Use outcomes to secure treatment coverage. Many
patients cannot afford cancer treatments costing greater
than $100,000/year.
15

16
FORMOREINFORMATIONPLEASEVISIT
OURPRECISIONONCOLOGYWEBSITE
Selen Karaca-Griffin
Business Strategy Senior Manager, Accenture Strategy
https://www.linkedin.com/in/selen-karaca-griffin-
95a64625/
Dr. Boris Bogdan
Managing Director, Lead – Global Precision Oncology
and PHC, Accenture Life Sciences
https://www.linkedin.com/in/borisbogdan/
CONTACT US STAY CONNECTED
linkedin.com/company/accenture_life_sciences
@AccentureLifeSci
www.accenture.com/lifesciencesblog

The Science of Launching and Achieving Growth in Oncology

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to The Science of Launching and Achieving Growth in Oncology

Similar to The Science of Launching and Achieving Growth in Oncology (20)

More from accenture

More from accenture (20)

Recently uploaded

Recently uploaded (20)

The Science of Launching and Achieving Growth in Oncology